Psychedelics

Monday Nov 08, 2021 - 9:56 am

InvestorNewsBreaks – Wonderland: Miami to Showcase Top Companies, Latest IPOs and Recent Developments in Psychedelics

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting the upcoming Wonderland Miami Conference. The event, designed to provide attendees with insights into some of the top companies, latest IPOs, newest opportunities and most recent developments within the space, is slated to take…

Tuesday Nov 02, 2021 - 2:47 pm

InvestorNewsBreaks – Why Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Is ‘One to Watch’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Founded in 2020 based on delivering to significant unmet need in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other disorders. “The company currently…

Monday Nov 01, 2021 - 11:42 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is nearing the launch of a phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (“PWS”), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. Tryp also plans to execute phase 2b clinical trials for…

Wednesday Oct 27, 2021 - 11:03 am

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speakers for World’s Premiere Psychedelic, Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that COMPASS Pathways execs George Goldsmith and Ekaterina Malievskaia MD will be featured speakers at next month’s Meet Delic event. Meet Delic is a revolutionary, two-day immersive edutainment experience designed to gather together the world's leading psychedelic and wellness thought and business leaders. The two-day event…

Tuesday Oct 26, 2021 - 1:04 pm

InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”). Aragen is a global leader in providing discovery, development and manufacturing solutions…

Tuesday Oct 26, 2021 - 11:31 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. The study focuses on using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The word psychedelic means ‘mind-manifesting,’ but what has…

Tuesday Oct 26, 2021 - 10:09 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Upcoming Pain Therapeutics Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced that it will present at the 15th Annual Pain Therapeutics Summit. The event is slated to take place on Nov. 1-3, 2021, with Tryp’s presentation scheduled to begin at 11:15 a.m. Central Time / 12:15 p.m. Eastern Time on Nov. 1. Chairman and…

Tuesday Oct 19, 2021 - 10:31 am

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Founder of Synergy Soul to Headline at Meet Delic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Brittany Hoogenboom will serve as a keynote speaker at Meet Delic on Nov. 7, 2021. Hoogenboom is the owner and founder of Synergy Soul, a brand focused on personal transformation through a holistic, integrated approach to life, business and wealth. She is also a certified physical therapy assistant, reiki…

Tuesday Oct 19, 2021 - 9:52 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin’s research and development team has completed 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for…

Monday Oct 18, 2021 - 12:36 pm

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Leveraging Wide-Ranging Business, Eyeing Opportunity in Multibillion Industry

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is servicing the growing interest within the psychedelic drug market, projected to grow at a 12.36% CAGR from $4.75 billion in 2020 to $10.75 billion by 2027, through the expansion of its wide-ranging business. “Simultaneously and in line with its goal of enabling billions of people to live happier lives through the provision of…

Friday Oct 15, 2021 - 10:17 am

InvestorNewsBreaks – IBN and PsychedelicNewsWire to Heighten Visibility, Widen Reach of Upcoming Psychedelic Capital Conference

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that it will collaborate with Microdose Psychedelic Insights, a cutting-edge media company aiming to move the psychedelics industry to the forefront of modern medicine, for its upcoming event. The Psychedelic Capital Conference, set to be held in an entirely virtual format on Oct. 28, 2021, will feature the most innovative and cutting-edge companies, latest…

Tuesday Oct 12, 2021 - 11:19 am

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Duncan Trussell to Keynote at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Duncan Trussell will serve as a keynote speaker at Meet Delic on Nov. 6, 2021. An actor and stand-up comedian, Trussell co-created and appears in the Netflix animated series “The Midnight Gospel” and regularly travels the country performing comedy at festivals and shows. He also hosts the “Duncan Trussell…

Tuesday Oct 12, 2021 - 11:07 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of…

Tuesday Oct 12, 2021 - 10:29 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. According to the update, the application, governed by the Patent Cooperation Treaty (“PCT”), brings the potential to obtain patent coverage in 153 countries. “The continued…

Monday Oct 11, 2021 - 1:28 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset…

Monday Oct 11, 2021 - 1:09 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://ibn.fm/NCORl). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin…

Tuesday Oct 05, 2021 - 9:44 am

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world's leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, which will take place on Nov. 6, 2021. Maloof has…

Monday Sep 27, 2021 - 11:58 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin…

Friday Sep 24, 2021 - 1:30 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several milestones, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than CA$120 million. In addition, Cybin…

Wednesday Sep 22, 2021 - 11:25 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD,…

Tuesday Sep 14, 2021 - 1:56 pm

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Recent Acquisition Boosting Psychedelic Drug Development Program

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, announced its most recent acquisition and wholly controlled subsidiary, Adelia Therapeutics Inc., is already reporting success, having achieved certain milestones for the year. Cybin closed on the acquisition of Adelia late last year, with the company noting several key advantages gained through the transaction. According to…

Friday Sep 10, 2021 - 11:48 am

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Keynote Speaker Chris Ryan, Ph.D., for World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Chris Ryan, Ph.D., will serve as one of the headline speakers on Nov. 7, 2021, at Meet Delic, the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business. In his keynote, “Psychedelics and the Search for Truth,” Ryan will explore the emerging potential…

Tuesday Sep 07, 2021 - 2:35 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A…

Wednesday Sep 01, 2021 - 11:12 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright Global Investment Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO of Tryp, will provide an overview of the company and…

Wednesday Sep 01, 2021 - 9:25 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports on Milestone Achievements Reached by Subsidiary

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., its wholly controlled subsidiary, has reached key milestones for Year 1 Q3. The milestones were outlined in last year’s transaction agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous shareholders of Adelia. Based on the agreement, 9,392.6 Class B common shares in the capital…

Friday Aug 27, 2021 - 11:03 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed…

Thursday Aug 26, 2021 - 9:39 am

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Releases First-of-Its-Kind Digital Therapeutics Platform to Partner Clinics in North America

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, today announced the release of the minimum viable product version of iSTRYM, its digital therapeutics platform (“DTx”) for psychedelics, into partner clinics across North America. According to the update, the company will begin full commercial deployment to all clinics in the first quarter of 2022. MINDCURE…

Tuesday Aug 24, 2021 - 10:31 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Psychotherapy Training for Upcoming Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it has completed the training of psychotherapists for its upcoming phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. According to the update, the training was conducted by Fluence, which is led by researchers and psychotherapists with direct…

Monday Aug 23, 2021 - 12:07 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp delves into the evolution of psychedelics from an ancient antidote…

Thursday Aug 19, 2021 - 9:15 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under the Patent Cooperation Treaty (“PCT”). One of the patent applications…

Tuesday Aug 17, 2021 - 2:51 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a clinical trial for eating disorders including binge eating and hypothalamic…

Tuesday Aug 17, 2021 - 9:42 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. nonprovisional application claiming priority to the May 2021 PCT application.…

Thursday Aug 12, 2021 - 10:33 am

InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Headline Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Luke Storey will serve as one of the headline speakers at Meet Delic. The world's premiere psychedelic and wellness edutainment event, Meet Delic caters to curious newcomers as well as business and thought leaders. A motivational speaker, meditation and metaphysics teacher and lifestyle design expert, Storey is the creator and host…

Wednesday Aug 11, 2021 - 2:16 pm

InvestorNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is…

Tuesday Aug 03, 2021 - 1:07 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s focus on psychedelics, how he got involved with Tryp and…

Wednesday Jul 28, 2021 - 10:25 am

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at…

Wednesday Jul 21, 2021 - 1:27 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Moving Psychedelic Therapeutics Field Forward Through Partnership

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress. The recently launched EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine. Cybin has co-sponsored the study…

Wednesday Jul 21, 2021 - 10:02 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. According to the update, the open-label trial will evaluate the…

Tuesday Jul 13, 2021 - 1:16 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s initiative that qualifies every resident to at least one free…

Tuesday Jul 13, 2021 - 9:36 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also advancing the build-out of its digital therapeutics strategy, with the objective of evolving its programs beyond the psychedelic molecule into an eco-system with potential to improve…

InvestorNewsBreaks

NewsBreak Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions